Now let me produce the final calibrated review.

## Summary

This paper empirically evaluates small language models (SLMs) and small vision-language models (SVLMs) against larger medically-adapted models on two clinical tasks: patient question summarization (MeQSum) and radiology report generation (MIMIC-CXR). It proposes a "Collapse Analysis" framework with dimensions including Task Adherence, Hallucination Rate, Concept Recall, and Prompt Robustness, and reports a "minimum viable scale" threshold around 1B parameters below which quality degrades sharply. The paper provides useful breadth (nine model configurations across five families) but its central claims are undermined by an asymmetric evaluation design and undefined metrics, making the headline findings difficult to assess.

## Strengths

- **Broad model coverage with multiple adaptation strategies.** The paper evaluates models from SmolLM2 (135M–1.7B), Gemma 3 (270M–4B), LLaMA 3.2 (1B), Florence 2 (0.77B), and Qwen2.5-VL (3B) across zero-shot, few-shot, and LoRA fine-tuning settings — a non-trivial benchmarking effort that provides useful data for the community.
- **Practically relevant question.** The study targets a genuine deployment need: whether small, privacy-preserving models can serve as efficient alternatives to large API-dependent medical LLMs for on-premise clinical text summarization (lines 53–55).
- **The VLM comparison is internally consistent.** Finding 2 (small VLMs lag behind large VLMs even after fine-tuning, Table 4) is supported by the data and contrasts usefully with the text-only results, suggesting that visual reasoning genuinely demands more capacity.

## Weaknesses

### Major

1. **Asymmetric comparison undermines the headline claim about model scale.** The paper claims that "small LMs outperformed large LMs across all metrics" and that "model scale can be traded for adapter efficiency without sacrificing quality" (abstract, lines 191, 231, 247). However, the evidence rests entirely on comparing **LoRA-fine-tuned small models against large models evaluated with ICL (2-shot) only**. Figure 3 shows that BioMistral 7B, Med-LLaMA 8B, and OpenBioLLM 8B have no LoRA scores — only ICL scores. Line 120 states: "To further enhance **small-model capabilities**, we applied three parameter-efficient fine tuning(PEFT) methods-LoRA...to each **small LLM**." The paper never applies PEFT to the large models. What the experiment actually demonstrates is that fine-tuning helps small models (a well-known result), not that scale is irrelevant when both are equally adapted. The large models are already domain-adapted through medical pre-training, so the proper test of the paper's thesis would require either fine-tuning the large models as well or comparing both in ICL-only settings.

2. **Collapse Analysis metrics are not defined.** The paper's second claimed contribution (lines 24–26) introduces Task Adherence, Hallucination Rate, Clinical Concept Recall, Prompt Robustness, and a composite "Readiness Score" (Table 3), but provides **no operational definitions** for any of them. How is hallucination rate computed (automated classifier, human annotation, rule-based)? What constitutes a hallucination in clinical text? How is Task Adherence scored on a 0–1 scale? The paper lists only dimension names and numerical values. Since the most practically significant finding — a "safety collapse" with hallucination rates spiking to 18.3% (SmolLM2-360M) and 75% (Gemma-3-270M) below 1B parameters — depends entirely on these undefined metrics, the framework is neither interpretable nor reproducible as presented.

3. **No statistical significance or variance reported.** All results (Tables 2, 3, 4; Figure 3) are point estimates without error bars, confidence intervals, standard deviations, or significance tests. The test set is 250 samples (line 82). With this sample size, reported differences of 1–3% (e.g., SmolLM2's ~1% MEDCON drop under few-shot, line 112) and even the large hallucination-rate gaps between model sizes cannot be assessed for robustness.

### Minor

4. **QLoRA claimed but results absent.** The paper lists QLoRA among the applied methods (lines 120, 247) but never reports any QLoRA results. The claim "we implemented PEFT techniques (LoRA; QLoRA)" overstates what was evaluated.

5. **Undefined dataset name.** Line 231 refers to "MeQ-Small corpus," which is never defined; the only dataset introduced for text summarization is MeQSum (line 80).

6. **Unresolved table reference.** Line 219 references "Table ??" — a placeholder that was not resolved.

### Trivial

None.

## Nice-to-Haves

- Apply LoRA fine-tuning to at least one representative large medical LM to enable a symmetric comparison.
- Provide full methodological details for every Collapse Analysis dimension (scoring procedure, annotation pipeline, inter-rater agreement or automated verification).
- Report variance estimates (e.g., bootstrap confidence intervals or standard deviations across runs) for all metrics.
- Either report QLoRA results or remove the claim.
- Resolve the "Table ??" placeholder and clarify "MeQ-Small."

## Removed Points

- *"The claim about competitive zero-shot performance is unsupported"_ — **Removed.** Table 2 shows SmolLM2-1.7B achieves BERTScore 0.9007 (highest) and MEDCON 0.271 — competitive with large models. The paper only claims "competitive" in this context, not "exceed." The harsh critic's concern here overstates the mismatch between claim and evidence.
- *"Physician preference for larger models"* as a weakness — **Removed.** The paper acknowledges this (lines 48–52) and positions SLMs for information extraction rather than open-ended reasoning. This is appropriate scoping, not a weakness.
- *"Small models only competitive, not exceeding, in zero-shot"_ — **Removed.** As noted above, the zero-shot claims in the paper are appropriately hedged. The overclaiming occurs in the fine-tuned comparison, already covered by Weakness 1.

## Novel Insights

None beyond the paper's own contributions.

## Suggestions

1. **Reframe the headline claims.** The finding that small models + LoRA can approach or match large medical LMs used with ICL is practically useful and worth reporting — but it should be described as exactly that, not as evidence that model scale is irrelevant.
2. **Define every Collapse Analysis metric** with enough detail to be independently reproduced.
3. **Report variance** for all metrics — at minimum, bootstrap confidence intervals on the 250-sample test set.
4. **Add a LoRA-fine-tuned large model** to the comparison (even one, e.g., BioMistral-7B + LoRA) to make the central experiment symmetric and the conclusions sound.
5. **Fix the presentation artifacts** (Table ??, MeQ-Small, QLoRA mention without results).

## Score and Decision

**Calibration anchors considered:**

| File | Avg Score | Round | Itemized? | Comparison |
|------|-----------|-------|-----------|------------|
| aP3OBwf8dk (Small specialized LMs, novel method) | 6.00 | Bracket | Yes | Higher-quality paper with novel method (SLM-is) and thorough evaluation; no asymmetric comparison or undefined metrics issues. Our paper is substantially weaker. |
| eENHKMTOfW (Training mice to compete with elephants) | 6.00 | Bracket | Yes | Well-executed study on fine-tuning small LLMs with comprehensive experiments; lacks our structural evaluation issues. Our paper is weaker. |
| YAMlVKRLnc (ClinicalLab) | 4.20 | Bracket | Yes | Medical evaluation benchmark with some asymmetric evaluation issues; has defined metrics and end-to-end evaluation though. Our paper's undefined-metrics problem is more severe. |
| gYcft1HIaU (Do LLMs Master Clinical Knowledge?) | 4.33 | Bracket | Yes | Medical LLM evaluation with overclaiming issues; experiments only in Chinese limited generalizability. Our paper has broader model coverage but weaker evaluation design. |
| jgVqCCg5XX (Revisiting Scaling Effects of LLMs on Medical Reasoning) | 4.00 | Narrow | Yes | Most directly comparable — medical scaling study with missing confidence intervals and limited model diversity. Our paper has more models but the asymmetric comparison and undefined metrics are more fundamental flaws. |
| K1bv86Uvbp (LLMs for Biomedical KG Construction) | 3.00 | Narrow | Yes | Lower quality; unclear methodology, hard-to-believe results, lack of scientific rigor. Our paper is clearly better than this anchor. |

**Round-1 bracket:** 3.0 – 5.0, narrowed from comparative analysis.

**Final placement:** Score **3.5**. The paper sits below the 4.0 anchor (jgVqCCg5XX) because its two major weaknesses — asymmetric comparison (no shared weight with any anchor's heavy negative items; unique to this paper's evaluation design) and completely undefined Collapse Analysis metrics (more severe than the "missing confidence intervals" weakness shared with jgVqCCg5XX) — are more fundamental than the issues in the 4.0-range anchors. However, it sits above the 3.0 anchor (K1bv86Uvbp) because its basic experimental setup (standard metrics BLEU/ROUGE/BERTScore/MEDCON applied to two established datasets) is sound, the model coverage is broad, and the VLM finding (Finding 2) is internally consistent. The paper provides useful empirical data but the central claims about scale and the "collapse" framework cannot be accepted as presented.

MY FINAL SCORE: <score>3.5</score>
MY FINAL DECISION: <decision>Reject</decision>